2022
Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women
Baker T, Croop R, Kamen L, Price P, Stock D, Ivans A, Bhardwaj R, Anderson M, Madonia J, Stringfellow J, Bertz R, Coric V, Hale T. Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women. Breastfeeding Medicine 2022, 17: 277-282. PMID: 35049333, PMCID: PMC8972016, DOI: 10.1089/bfm.2021.0250.Peer-Reviewed Original ResearchConceptsRelative infant doseHealthy lactating womenHuman milkMaternal doseInfant doseLactating womenSmall-molecule calcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptor antagonistMean relative infant doseStudy drug administrationSingle-center studyMaternal body weightPeptide receptor antagonistBody mass indexTreatment of migraineHuman milk samplesPlasma drug concentration ratioDrug concentration ratioWeight-adjusted basisConcentration-time profilesHours postdoseMaternal dosesUncomplicated deliveryMass indexMean age
2019
Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal Of Medicine 2019, 381: 142-149. PMID: 31291516, DOI: 10.1056/nejmoa1811090.Peer-Reviewed Original ResearchConceptsPercentage of patientsPeptide receptor antagonistPlacebo groupMigraine attacksBothersome symptomsReceptor antagonistCalcitonin gene-related peptide receptor antagonistCalcitonin gene-related peptide receptorGene-related peptide receptorOral Calcitonin GeneSingle migraine attackAcute migraine treatmentCommon adverse eventsPrimary end pointPhase 3 trialUrinary tract infectionOverall mean agePathogenesis of migraineModified intentionAdverse eventsTract infectionsTreat analysisMean ageMigraine treatmentCalcitonin gene